YCBD - cbdMD Inc Stock Price, Fair Value and News

0.72USD+0.01 (+1.41%)Market Closed

Market Summary

USD0.72+0.01

Market Closed

1.41%

YCBD Stock Price

View Fullscreen

YCBD RSI Chart

YCBD Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

0.12

EV/EBITDA

-0.03

Price/Free Cashflow

-1.62

YCBD Price/Sales (Trailing)

YCBD Profitability

Operating Margin

64.10%

EBT Margin

-96.57%

Return on Equity

-701.44%

Return on Assets

-148.81%

Free Cashflow Yield

-61.62%

YCBD Fundamentals

YCBD Revenue

Revenue (TTM)

22.4M

Rev. Growth (Yr)

-26.85%

Rev. Growth (Qtr)

-10.4%

YCBD Earnings

Earnings (TTM)

-21.7M

Earnings Growth (Yr)

-125.21%

Earnings Growth (Qtr)

-202.11%

Breaking Down YCBD Revenue

Last 7 days

5.9%

Last 30 days

-21.7%

Last 90 days

4.4%

Trailing 12 Months

-62.7%

How does YCBD drawdown profile look like?

YCBD Financial Health

Current Ratio

1.07

YCBD Investor Care

Shares Dilution (1Y)

35.51%

Diluted EPS (TTM)

-12.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	22.4M	0	0	0
2023	30.1M	27.7M	25.1M	24.2M
2022	41.5M	39.1M	37.1M	33.5M
2021	48.6M	49.2M	47.3M	44.1M
2020	39.8M	40.8M	43.2M	45.9M
2019	14.3M	21.2M	28.1M	37.8M
2018	6.8M	8.2M	459.1K	7.4M
2017	4.0M	4.7M	5.4M	5.7M
2016	0	0	2.6M	3.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of cbdMD Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	raines william f iii	acquired	-	-	4,000	-
Mar 29, 2024	stephen scott g.	acquired	-	-	4,000	-
Mar 29, 2024	sellers bakari t.	acquired	-	-	4,000	-
Mar 29, 2024	swift sibyl nichole	acquired	-	-	4,000	-
Jan 11, 2024	coffman raymond scott	acquired	-	-	13,011	-
May 03, 2023	kennedy thomas ronan	bought	-10,500	2.1	-5,000	interim ceo and cfo
Feb 17, 2023	stephen scott g.	acquired	-	-	5,000	-
Feb 17, 2023	swift sibyl nichole	acquired	-	-	5,000	-
Feb 17, 2023	raines william f iii	acquired	-	-	5,000	-
Feb 17, 2023	sellers bakari t.	acquired	-	-	5,000	-

Which funds bought or sold YCBD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-1.33	-9.00	69.00	-%
May 15, 2024	MORGAN STANLEY	reduced	-74.07	-1,310	580	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-54.00	455	-%
May 15, 2024	Penserra Capital Management LLC	sold off	-100	-12,000	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-1.00	-	-%
May 15, 2024	CSS LLC/IL	unchanged	-	9,523	61,602	-%
May 15, 2024	Royal Bank of Canada	reduced	-55.26	-1,000	1,000	-%
May 14, 2024	Qube Research & Technologies Ltd	new	-	279	279	-%
May 14, 2024	NewEdge Advisors, LLC	unchanged	-	-	5.00	-%
May 14, 2024	HHM Wealth Advisors, LLC	unchanged	-	-7.00	63.00	-%

Are Funds Buying or Selling YCBD?

Are funds buying YCBD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own YCBD

No. of Funds

Unveiling cbdMD Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 03, 2023	american media inc	6.5%	4,242,424	SC 13G
Jun 21, 2022	coffman raymond scott	27.8%	16,731,906	SC 13D/A
May 19, 2022	coffman raymond scott	27.8%	16,731,906	SC 13D/A
Mar 02, 2022	coffman raymond scott	27.6%	16,383,987	SC 13D/A
Dec 30, 2021	coffman raymond scott	27.6%	16,092,341	SC 13D/A
Aug 19, 2021	coffman raymond scott	27.6%	0	SC 13D/A
May 19, 2021	coffman raymond scott	27.1%	15,453,366	SC 13D/A
Mar 15, 2021	coffman raymond scott	26.8%	0	SC 13D/A
Feb 24, 2021	coffman raymond scott	24.4%	12	SC 13D/A
Mar 03, 2020	justice family office llc	5.9%	0	SC 13G/A

Recent SEC filings of cbdMD Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 05, 2024	3	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	424B3	Prospectus Filed
Apr 02, 2024	8-K	Current Report
Mar 27, 2024	424B4	Prospectus Filed
Mar 26, 2024	EFFECT	EFFECT

Peers (Alternatives to cbdMD Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

cbdMD Inc News

Latest updates

cbdMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-10.4%	4,816,444	5,375,630	5,765,701	6,462,965	6,584,666	6,240,526	8,448,497	8,868,093	9,948,858	9,856,767	10,390,168	11,352,585	12,457,386	13,131,946	12,247,100	10,809,387	9,703,800	10,412,491	9,908,777	9,734,459	7,752,478
Cost Of Revenue	-1.2%	1,795,790	1,817,907	2,161,900	2,273,839	2,224,512	2,517,452	2,891,067	2,660,185	3,186,564	4,328,310	4,050,710	3,370,952	3,643,127	3,430,274	5,334,090	3,748,024	2,732,076	3,700,537	4,127,400	2,929,160	1,914,716
Gross Profit	-27.5%	2,580,728	3,557,498	3,548,845	3,845,541	4,015,508	3,567,766	4,968,556	5,932,708	6,442,322	4,993,512	5,742,617	7,189,571	8,155,484	8,898,028	6,365,827	6,888,521	6,666,960	6,447,699	5,416,736	5,075,989	3,721,862
Operating Expenses	-	-	-	-	-	-	-	-	-	11,452,700	11,955,284	12,755,319	13,865,191	12,323,207	10,657,973	10,896,900	8,226,029	12,267,637	12,560,297	10,627,860	11,542,628	5,749,463
EBITDA Margin	-17.2%	-0.95	-0.81	-0.90	-0.76	-1.69	-1.62	-1.86	-1.47	-0.58	-0.74	-0.49	-0.52	-	-	-	-	-	-	-	-	-
Interest Expenses	-4301.7%	-18,399	-418	53,654	-1,246	-1,946	29,119	23,117	-1,551	-2,086	-3,234	-5,358	-2,582	-10,603	-10,386	-12,617	3,436	35,607	7,267	24,882	6,229	6,274
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-462,000	103,000	-536,000	332,000	1,345,300	-	-	-2,240,300	-63,000	-1,088,000	-1,075,000
Earnings Before Taxes	-202.1%	-3,010,562	-996,501	-15,874,940	-1,770,404	-1,336,802	-3,956,062	-14,630,917	-31,634,143	-4,657,215	-19,160,904	-3,156,081	1,640,288	-13,046,474	-9,727,621	-5,363,561	-8,944,921	14,883,772	10,730,665	14,249,202	-28,021,178	-32,925,877
EBT Margin	-16.9%	-0.97	-0.83	-0.92	-0.78	-1.71	-1.64	-1.89	-1.50	-0.61	-0.77	-0.51	-0.54	-	-	-	-	-	-	-	-	-
Net Income	-202.1%	-3,010,562	-996,501	-15,874,941	-1,770,404	-1,336,802	-3,956,062	-14,631,432	-31,634,143	-4,657,216	-19,160,904	-3,026,082	1,537,288	-12,510,474	-9,395,621	-6,258,562	-8,952,702	14,883,772	12,929,763	11,884,544	-29,202,956	-31,850,274
Net Income Margin	-16.9%	-0.97	-0.83	-0.92	-0.78	-1.71	-1.64	-1.89	-1.50	-0.61	-0.75	-0.49	-0.54	-	-	-	-	-	-	-	-	-
Free Cashflow	-140.8%	-699,448	-290,515	-383,681	-342,962	-1,631,230	-2,241,727	-2,152,140	-2,459,358	-5,344,827	-5,699,505	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.6%	14,550	15,095	16,195	32,970	33,684	35,727	40,792	57,138	92,988	99,327	124,883	115,522	121,058	124,079	110,843	111,311	112,583	101,797	94,518	100,909	94,835
Current Assets	0.6%	7,410	7,366	8,070	10,091	10,146	11,529	16,012	19,858	24,327	29,679	36,502	29,983	34,746	37,375	23,712	24,112	24,885	14,874	15,743	22,186	14,144
Cash Equivalents	39.9%	2,105	1,505	1,798	2,847	1,719	3,353	6,720	9,554	13,337	19,697	26,411	18,984	23,712	28,764	14,825	15,006	14,836	3,661	4,690	11,633	4,640
Inventory	-	3,452	-	4,236	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,116	2,065
Net PPE	-15.5%	668	790	717	700	798	901	823	775	2,335	2,504	2,562	2,775	2,977	3,084	3,183	3,068	3,224	2,158	1,716	1,017	817
Goodwill	-	-	-	-	-	-	-	-	11,996	42,773	56,671	56,671	54,670	54,670	54,670	54,670	54,670	54,670	54,670	54,670	55,134	55,144
Liabilities	42.3%	11,463	8,058	7,164	7,238	7,898	9,136	9,367	10,538	12,965	14,927	21,741	26,242	35,173	38,359	31,661	27,731	20,426	46,272	56,914	75,763	108,251
Current Liabilities	16.2%	6,937	5,972	4,670	4,384	4,679	5,552	5,286	5,725	5,785	6,761	6,917	6,750	6,864	6,737	7,689	4,386	5,792	5,481	3,710	2,330	1,871
Long Term Debt	-	-	-	9*	819*	-	-	125	128	78.00	93.00	109	124	-	-	264	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	9*	819*	-	-	125	128	78.00	93.00	109	124	-	-	264	-	-	-	-	-	-
Shareholder's Equity	-56.1%	3,087	7,037	9,031	25,732	25,786	26,591	31,424	46,600	80,023	84,400	103,142	89,280	85,885	85,720	79,182	83,580	92,158	55,524	37,604	25,146	-
Retained Earnings	-2.3%	-180,371	-176,360	-174,363	-157,488	-154,717	-152,380	-147,423	-131,791	-99,156	-93,499	-73,337	-68,977	-69,954	-56,884	-47,388	-41,029	-31,977	-46,760	-59,610	-70,782	-43,083
Additional Paid-In Capital	0.0%	183,457	183,390	183,387	183,212	180,497	178,905	178,842	178,327	179,116	177,836	176,417	158,198	155,780	142,549	126,518	124,558	124,083	102,257	97,187	96,130	28,383
Shares Outstanding	2.8%	3,045	2,961	2,961	2,855	1,457	1,341	1,348	1,316	1,313	1,285	1,284	1,259	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-229	1,274
Float	-	-	-	-	-	12,718	-	-	-	42,426	-	-	-	-	-	-	-	30,947	-	-	-	42,357

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-565.0%	-704	-105	-263	-240	-1,733	-2,064	-1,925	-2,370	-5,202	-5,468	-4,334	-4,608	-2,958	-2,192	-387	-1,130	-4,273	-4,873	-6,322	-4,592	-3,299
Share Based Compensation	-	-	-	-	-	-	-	-	-	292	505	491	356	203	249	509	419	430	543	436	1,860	19.00
Cashflow From Investing	102.5%	5.00	-184	-120	-102	1,102	-177	96.00	-410	-142	-231	-2,030	455	-1,423	447	282	-55.40	-1,240	-555	-527	-246	-92.48
Cashflow From Financing	52079.2%	1,300	-2.50	-665	1,471	-1,002	-1,125	-1,003	-1,001	-1,015	-1,015	13,792	-574	-669	15,685	-76.07	1,356	16,689	4,401	-93.95	11,833	-
Dividend Payments	-	-	-	-	-	-	-	-	-	1,001	1,001	1,334	560	560	100	100	100	100	67.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

YCBD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Gross Sales	$ 4,816,444	$ 6,584,666	$ 10,192,075	$ 12,825,191
Allowances	(439,926)	(344,646)	(440,152)	(499,954)
Total Net Sales	4,376,518	6,240,020	9,751,923	12,325,237
Cost of sales	1,795,790	2,224,512	3,613,698	4,741,964
Gross Profit	2,580,728	4,015,508	6,138,225	7,583,273
Operating expenses	4,131,719	5,416,151	8,755,053	13,030,097
Loss from operations	(1,550,991)	(1,400,643)	(2,616,828)	(5,446,824)
(Increase) decrease of contingent liability	4,828	48,000	74,580	109,000
(Increase) decrease in fair value of convertible debt	(1,446,000)	0	(1,446,000)	0
Other income	0	17,787	0	49,543
Interest expense	(18,399)	(1,946)	(18,817)	(4,583)
Loss before provision for income taxes	(3,010,562)	(1,336,802)	(4,007,065)	(5,292,864)
Net Loss	(3,010,562)	(1,336,802)	(4,007,065)	(5,292,864)
Preferred dividends	1,000,500	1,000,500	2,001,000	2,001,002
Net Loss attributable to cbdMD, Inc. common shareholders	$ (4,011,062)	$ (2,337,302)	$ (6,008,065)	$ (7,293,866)
Net Loss per share:
Basic earnings per share (in dollars per share)	$ (1.35)	$ (1.74)	$ (2.03)	$ (5.43)
Diluted earnings per share (in dollars per share)	$ (1.35)	$ (1.74)	$ (2.03)	$ (5.43)
Weighted average number of shares Basic: (in shares)	2,961,057	1,345,589	2,961,000	1,343,394
Weighted average number of shares Diluted: (in shares)	2,961,057	1,345,589	2,961,000	1,343,394

YCBD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,105,396	$ 1,797,860
Accounts receivable, net of allowance for credit losses of $179,419 and $42,180, respectively	868,217	1,216,090
Inventory	3,174,005	4,052,972
Inventory prepaid	277,794	182,675
Prepaid sponsorship	52,078	70,061
Prepaid expenses and other current assets	932,770	750,383
Total current assets	7,410,260	8,070,041
Other assets:
Property and equipment, net	667,979	716,579
Operating lease assets	2,766,290	3,350,865
Deposits for facilities	132,203	138,708
Intangible assets	2,873,406	3,219,090
Investment in other securities, noncurrent	700,000	700,000
Total other assets	7,139,878	8,125,242
Total assets	14,550,138	16,195,283
Current liabilities:
Accounts payable	1,291,306	1,906,319
Accrued expenses	1,282,028	629,648
Accrued dividends	2,668,000	667,000
Deferred revenue	468,472	187,793
Operating leases – current portion	1,226,764	1,277,089
Note payable	0	2,492
Total current liabilities	6,936,570	4,670,341
Long term liabilities:
Convertible notes	2,702,000	0
Other long term liabilities	0	9
Operating leases - long term portion	1,824,721	2,403,286
Contingent liability	0	90,363
Total long term liabilities	4,526,721	2,493,658
Total liabilities	11,463,291	7,163,999
Commitments and Contingencies (Note 11)
cbdMD, Inc. shareholders' equity:
Preferred stock, authorized 50,000,000 shares, $0.001 par value, 5,000,000 and 5,000,000 shares issued and outstanding, respectively	5,000	5,000
Common stock, authorized 150,000,000 shares, $0.001 par value, 3,045,204 and 2,960,573 shares issued and outstanding, respectively	3,045	2,961
Additional paid in capital	183,456,639	183,387,095
Comprehensive other expense	(6,000)	0
Accumulated deficit	(180,371,836)	(174,363,772)
Total cbdMD, Inc. shareholders' equity	3,086,847	9,031,284
Total liabilities and shareholders' equity	$ 14,550,138	$ 16,195,283

About cbdMD Inc

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.

CEO	Mr. T. Ronan Kennedy
WEBSITE	cbdmd.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	90

cbdMD Inc Frequently Asked Questions

What is the ticker symbol for cbdMD Inc? What does YCBD stand for in stocks?

YCBD is the stock ticker symbol of cbdMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of cbdMD Inc (YCBD)?

As of Fri May 17 2024, market cap of cbdMD Inc is 2.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YCBD stock?

You can check YCBD's fair value in chart for subscribers.

What is the fair value of YCBD stock?

You can check YCBD's fair value in chart for subscribers. The fair value of cbdMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of cbdMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YCBD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is cbdMD Inc a good stock to buy?

The fair value guage provides a quick view whether YCBD is over valued or under valued. Whether cbdMD Inc is cheap or expensive depends on the assumptions which impact cbdMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YCBD.

What is cbdMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, YCBD's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 0.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YCBD PE ratio will change depending on the future growth rate expectations of investors.